Management of Crohn's Disease Medications During Small Bowel Obstruction
Continue mercaptopurine but hold budesonide during the acute small bowel obstruction, then reassess based on the clinical scenario and need for surgical intervention.
Rationale and Clinical Approach
Mercaptopurine Management
Mercaptopurine should generally be continued during the acute SBO episode. The evidence supports this approach for several key reasons:
Thiopurines (mercaptopurine) are maintenance therapy agents that work slowly and are not used for acute flare management 1, 2. Stopping them abruptly provides no immediate benefit for the obstruction itself.
Risk of disease flare outweighs acute concerns: Discontinuing immunosuppression risks triggering a Crohn's flare that could complicate the clinical picture and potentially necessitate corticosteroids or hospitalization 3. The 2020 British Society of Gastroenterology guidance explicitly states that "patients are advised not to stop or reduce their medication without discussing with the IBD team, due to the risk of flare" 3.
Historical evidence supports continuation: A 1983 study demonstrated that patients with small bowel obstruction in Crohn's disease who were maintained on 6-mercaptopurine (with or without sulfasalazine) had successful nonoperative management with good quality of life outcomes 4. This suggests mercaptopurine does not worsen obstruction and may help prevent inflammatory recurrence.
Key caveat: If the patient requires emergency surgery or develops septic complications (abscess, perforation), temporarily hold mercaptopurine perioperatively and restart once surgical recovery is established and infection is controlled.
Budesonide Management
Budesonide should be held during the acute SBO for the following reasons:
Budesonide is not indicated for maintenance therapy: Multiple guidelines explicitly recommend against using oral budesonide to maintain remission in Crohn's disease 1, 2. The 2019 Canadian guidelines state: "we suggest against the use of oral budesonide to maintain complete remission" (conditional recommendation, low-quality evidence) 1.
Limited systemic absorption in SBO: With small bowel obstruction, the extended-release formulation cannot be properly absorbed in its intended ileal/right colonic location 2, 5. The medication requires passage through the GI tract to reach its target site.
Corticosteroid risks during acute illness: If surgery becomes necessary, systemic corticosteroid effects (even from budesonide's limited bioavailability) increase infection risk and impair wound healing 3. The 2020 BSG guidance notes that "high dose steroids are an established risk factor for respiratory tract infection and opportunistic infection in IBD and septicaemia" 3.
FDA labeling considerations: The budesonide label warns about increased infection risk and notes that corticosteroids "can make current infections worse" 6. In the setting of potential bowel compromise or impending surgery, minimizing this risk is prudent.
Clinical Algorithm for Decision-Making
Immediate management (during SBO):
- Hold budesonide
- Continue mercaptopurine unless contraindicated (see below)
- Initiate conservative SBO management (NPO, NG decompression, IV fluids)
Assess for contraindications to continuing mercaptopurine:
- Signs of sepsis or intra-abdominal infection → hold mercaptopurine
- Neutropenia on admission labs → hold mercaptopurine
- Emergency surgery planned within 24-48 hours → hold mercaptopurine perioperatively
After SBO resolution (conservative management):
- Resume budesonide only if it was being used for active disease (though this contradicts guidelines for maintenance use)
- Continue mercaptopurine
- Consider transitioning from budesonide to appropriate maintenance therapy if not already established
If surgery is required:
- Hold both medications perioperatively
- Restart mercaptopurine once bowel function returns and no infection present (typically 5-7 days post-op)
- Do NOT restart budesonide for maintenance; consider appropriate step-up therapy if needed for disease control
Important Pitfalls to Avoid
Do not abruptly stop mercaptopurine "just because the patient is admitted" – this increases flare risk without addressing the obstruction 3.
Do not continue budesonide thinking it will help the obstruction – it won't reach its site of action and provides unnecessary corticosteroid exposure 1, 2.
Do not restart budesonide long-term after SBO resolution – it's ineffective for maintenance and the patient should be on appropriate maintenance therapy (which they are, with mercaptopurine) 1, 2.
Monitor for infection closely – the combination of Crohn's disease, potential bowel compromise, and immunosuppression creates infection risk. Check CBC, consider imaging if fever or peritoneal signs develop 7.
If the patient has been on budesonide chronically (despite guideline recommendations against this), do not stop it abruptly without stress-dose corticosteroid coverage if surgery is needed, as adrenal suppression may be present 6.